Your gifts move us one step closer to a cure for NETs.
What is Giving Tuesday?
After Black Friday and Cyber Monday comes the most generous day of all — Giving Tuesday, December 3, 2019. On this one day, the Neuroendocrine Tumor Research Foundation (NETRF) hopes to raise $100,000 to fund a Pilot Research Award in January 2020. Your gift will be put to work immediately in the search for a cure.
Thank You to Our Donors!
Your gift can help improve, extend, and save lives
Every Gift Will Be Matched
The Spark Hope campaign is fueled by a generous match by the Margie and Robert E. Petersen Foundation. Your gift to the Neuroendocrine Tumor Research Foundation today will be doubled.
Giving Tuesday Gifts will fund a Pilot Research Award
Pilot research awards for $100,000 fund a one-year research project to:
- Support proof-of-concept projects to investigate novel approaches to NETs.
- Fund scientists early in their careers so they can focus on NET research and commit to a career in this area.
- Help researchers gather data that can be used to secure larger grants from other sources.
Why we need your help to fund research
This is the kind of research that $100,000 can fund
Jennifer Chan, MD, MPH
Dana-Farber Cancer Institute, Boston, MA
David Morse, PhD
Moffitt Cancer Center, Tampa, FL
Renuka Iyer, MD
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Cabozantinib in NETs
This study analyzes data from a clinical trial of a drug called cabozantinib (currently approved for use in kidney and thyroid cancer) to see if those who responded (or those who didn’t) share any common molecules in their blood, body fluid, or tissue, called a biomarker. Biomarkers help predict who benefits most from treatment and helps doctor’s personalize care for individual patients to treat the specific characteristics of a tumor.
Lung PRRT Drug
This study will test a novel radiotherapy, 225Ac-dotatate, a derivative of Lu-177, in PRRT for lung NETs in laboratory models. This therapy emits alpha (α) particles instead of beta (β). Alpha particles are bigger, higher-powered, with a shorter reach, which researchers hope will be more effective in killing lung NET cells. Laboratory tests will help evaluate the therapy’s safety and efficacy to prepare for potential testing in humans.
This phase I study tests SurVaxM™ vaccine in combination with a somatostatin analog in patients with survivin-expressing NETs. The vaccine targets survivin, a protein that’s often highly expressed in lung, intestinal, and pancreatic NETs and associated with aggressive disease because of its ability to prevent tumor cell death.
Tell your friends you are helping to #CureNETs with a #GivingTuesday donation to NETRF